Comparative Pharmacology
Head-to-head clinical analysis: HYDROXYUREA versus OTREXUP PFS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDROXYUREA versus OTREXUP PFS.
HYDROXYUREA vs OTREXUP PFS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits ribonucleotide reductase, leading to decreased DNA synthesis and cell cycle arrest in S phase; also increases fetal hemoglobin production by inducing nitric oxide and altering erythroid progenitor signaling.
Methotrexate is a folate analog that inhibits dihydrofolate reductase, thereby blocking the synthesis of purines and pyrimidines, leading to inhibition of DNA synthesis and cell proliferation. It also has immunosuppressive and anti-inflammatory effects through modulation of adenosine pathways and cytokine release.
Oral: 15-20 mg/kg once daily (rounded to nearest 500 mg) for myeloproliferative disorders (e.g., essential thrombocythemia); 80 mg/kg every 3 days (as 35 mg/kg single dose) for sickle cell disease.
Methotrexate 7.5-15 mg subcutaneously once weekly. For rheumatoid arthritis, start at 7.5 mg weekly, titrate to 20-25 mg weekly as tolerated.
None Documented
None Documented
Clinical Note
moderateHydroxyurea + Digoxin
"Hydroxyurea may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateHydroxyurea + Digitoxin
"Hydroxyurea may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateHydroxyurea + Deslanoside
"Hydroxyurea may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateHydroxyurea + Acetyldigitoxin
"Hydroxyurea may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal half-life: 3.5–4.5 hours; clinical context: hematologic effects persist for 24-48 hours due to irreversible inhibition of ribonucleotide reductase.
5-8 hours (low-dose methotrexate); 8-15 hours (high-dose). Prolonged in renal impairment, third-space effusions, or concomitant NSAIDs.
Renal: approximately 80% (30-60% unchanged; remainder as metabolites). Fecal: <10%.
Renal excretion (80-90% unchanged) via glomerular filtration and tubular secretion; biliary/fecal elimination accounts for <10%.
Category A/B
Category C
Antimetabolite
Antimetabolite